News coverage about BioTelemetry (NASDAQ:BEAT) has been trending positive recently, according to AlphaOne. The research firm, a division of Accern, rates the sentiment of press coverage by analyzing more than 20 million blog and news sources in real time. AlphaOne ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. BioTelemetry earned a media sentiment score of 0.37 on AlphaOne’s scale. AlphaOne also gave news articles about the medical research company an impact score of 52 out of 100, indicating that recent press coverage is somewhat likely to have an impact on the stock’s share price in the near term.
Here are some of the media stories that may have impacted Alpha One’s analysis:
Shares of BioTelemetry (BEAT) opened at 28.50 on Tuesday. BioTelemetry has a 1-year low of $14.72 and a 1-year high of $34.00. The company has a market cap of $816.67 million, a price-to-earnings ratio of 17.80 and a beta of 0.90. The firm has a 50-day moving average price of $29.94 and a 200 day moving average price of $25.57. BioTelemetry (NASDAQ:BEAT) last announced its earnings results on Wednesday, May 3rd. The medical research company reported $0.16 earnings per share for the quarter, topping analysts’ consensus estimates of $0.14 by $0.02. BioTelemetry had a return on equity of 26.70% and a net margin of 7.58%. The firm had revenue of $55.88 million for the quarter, compared to the consensus estimate of $55.11 million. On average, analysts predict that BioTelemetry will post $0.89 EPS for the current fiscal year.
In related news, Director Robert J. Rubin sold 15,000 shares of BioTelemetry stock in a transaction that occurred on Monday, May 15th. The shares were sold at an average price of $28.14, for a total value of $422,100.00. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, SVP Fred Broadway sold 3,429 shares of BioTelemetry stock in a transaction that occurred on Monday, March 20th. The stock was sold at an average price of $26.90, for a total transaction of $92,240.10. Following the completion of the sale, the senior vice president now directly owns 25,420 shares in the company, valued at approximately $683,798. The disclosure for this sale can be found here. 11.00% of the stock is owned by insiders. BioTelemetry Company Profile